Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) is now available.
Shanghai Junshi Biosciences Co., Ltd. has announced that its board of directors will convene on August 26, 2025, to review and approve the company’s interim financial results for the first half of the year ending June 30, 2025. This meeting is significant as it will provide insights into the company’s financial health and operational performance, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biosciences industry. The company focuses on developing innovative therapies and products, with a market presence in the pharmaceutical sector.
Average Trading Volume: 12,377,720
Technical Sentiment Signal: Buy
Current Market Cap: HK$42.27B
Find detailed analytics on 1877 stock on TipRanks’ Stock Analysis page.